Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Exclusion Criteria

• •Subjects who have previously been exposed to neurotoxic agents including pyridoxine (\>100 mg/day), colchicine, allopurinol, or phenytoin;
• •Subjects with pre-existing comorbidities, such as: diabetes, uremia, significant peripheral vascular disease, HIV, or progressive or degenerative neurologic disorders (e.g., multiple sclerosis, B12 deficiency); cardiovascular valve disease, history of cardiovascular event,
• •Subjects with a history of lumbosacral laminectomy or radiculopathy;
• •Subjects who have been prescribed and taken gabapentin, pregabalin, or duloxetine currently or within the last 1 months)
• •Subjects who have established or suspected family history of inherited neuropathy.
• •Subjects unable to swallow indicated medication
• •Subjects in general with a medical condition, laboratory finding, or physical exam finding that precludes participation
• •Subject weight of ≥350 lbs.
• •Subjects who currently use disallowed concomitant medications
• •Subjects with any form of cardiac implants
• •Subjects who report recent febrile illness that precludes or delays participation
• •Subjects with pregnancy or lactation
• •Subjects with known allergic reactions to components of the study product(s)
• •Subjects receiving treatment with another investigational drug or other intervention
• •Subjects with a history of or current tobacco or illegal substance use
• •Subjects exhibiting significant psychiatric or cognitive impairment (dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation.